Malignant peripheral nerve sheath tumors – Outcomes and prognostic factors based on the reference center experience
- 1 December 2020
- journal article
- research article
- Published by Elsevier in Surgical Oncology
- Vol. 35, 276-284
Abstract
No abstract availableKeywords
Funding Information
- Les Laboratories Pierre Fabre
- Eli Lilly and Company
- Meso Scale Diagnostics
- Roche
- Bayer
- Novartis
- British Microcirculation & Vascular Biology Society
This publication has 33 references indexed in Scilit:
- Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1Neuro-Oncology, 2012
- Oncologic Outcomes of Sporadic, Neurofibromatosis-Associated, and Radiation-Induced Malignant Peripheral Nerve Sheath TumorsAnnals of Surgical Oncology, 2012
- Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas: A Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma GroupJournal of Clinical Oncology, 2012
- Malignant Peripheral Nerve Sheath Tumors (MPNST): The Mayo Clinic ExperienceAnnals of Surgical Oncology, 2011
- Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: Results of a pooled analysis from United States and European groupsEuropean Journal of Cancer, 2011
- First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC Soft Tissue and Bone Sarcoma Group studyAnnals of Oncology, 2010
- Clinical, Pathological, and Molecular Variables Predictive of Malignant Peripheral Nerve Sheath Tumor OutcomeAnnals of Surgery, 2009
- Malignant peripheral nerve sheath tumorsCancer, 2006
- Pediatric Malignant Peripheral Nerve Sheath Tumor: The Italian and German Soft Tissue Sarcoma Cooperative GroupJournal of Clinical Oncology, 2005
- Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosisEuropean Journal of Surgical Oncology, 1995